Recent Updates
Recently added Catalysts
PLSE Positive Sentiment

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Key Takeaway: Pulse Biosciences announced equity inducement grants to four new employees under Nasdaq Rule 5635(c)(4). The grants, totaling options for 6,300 shares, were approved on November 19, 2026. Each option has an exercise price of $44.41 and will vest over four years, contingent on continued employment.

Market Sentiment Analysis

POSITIVE FACTORS

  • Equity awards granted to four new employees.
  • Inducement options cover up to 6,300 shares.
  • Stock options priced at $44.41, aligning with market value.

Full Press Release Details

Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to four new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awards were approved and issued on November 19, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).
Pulse has awarded inducement options to four new employees to purchase, in aggregate, up to 6,300 shares of Company common stock. The Company’s independent Compensation Committee approved these awards as an inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $44.41 per share, which is equal to the closing price of the Company’s common stock on November 19, 2026, and all will be subject to time-based vesting over four years, with 1/4 of each award vesting annually, subject to the employee’s continued employment with Pulse Biosciences. The options are subject to the terms and conditions of the 2017 Inducement Equity Incentive Plan and the award agreements entered into with each recipient.
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as potential to improve the quality of life for patients. The Company’s proprietary nPulse™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. The Company is actively pursuing the development of its nPulse technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers.
Pulse Biosciences, nPulse, Vybrance, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Frequently Asked Questions

What are the inducement grants by Pulse Biosciences?

Pulse Biosciences granted equity awards to four new employees under Nasdaq Rule 5635.

How many shares were awarded in the inducement grants?

The grants cover options for a total of 6,300 shares.

What is the exercise price of the stock options?

The exercise price is set at $44.41 per share.

What is the vesting period for the stock options?

The options will vest over four years, with 1/4 vesting annually.

Last updated: Nov 20, 2026